Legend Biotech ADRs Climb on Preliminary Study Results for Non-Hodgkin Lymphoma Treatment
By Kelly Cloonan
American depositary receipts of Legend Biotech gained after the company said it observed promising early clinical evidence for a therapy aimed at treating non-Hodgkin lymphoma.
ADRs climbed 40% to $35.60 on Tuesday, and are now up 64% year to date.
In an ongoing Phase 1 study of 12 patients with relapsed or refractory B-cell non-Hodgkin lymphoma, Legend Biotech's CAR-T cell therapy LB2501 demonstrated a 100% objective response rate and an 83% complete response rate.
The company said the data supports the potential of an in vivo CAR-T approach in B-cell malignancies. LB2501 is designed to generate CAR-T cells directly within a patient following an intravenous infusion, eliminating the need for cell manufacturing and lymphodepletion, the company said.
"By generating CAR-T cells directly within the patient, this approach has the potential to simplify treatment delivery and expand access for patients who may not be able to receive traditional CAR-T cell therapies," Chief Executive Ying Huang said.
Non-Hodgkin lymphoma is one of the most common types of cancers in the U.S. The American Cancer Society estimates about 79,320 people will be diagnosed with non-Hodgkin lymphoma in 2026, and about 19,970 people will die from it.
B-cell lymphomas account for about 85% of NHL cases, Legend Biotech said.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
June 02, 2026 14:13 ET (18:13 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States